A CVS pharmacy in the Seattle suburb of Woodinville, Wash., will begin distributing the CVS-manufactured meningitis vaccine to more than 2,500 people in Seattle and Tacoma.
The program will start at 8 a.m. on Sunday.
CVS spokeswoman Natalie Stadler said Sunday the company is expecting about a third of the vaccine’s recipients to be vaccinated, but she declined to provide a breakdown.
Cuts to CVS and other health insurance providers have forced some of the nation’s largest drug companies to stop providing the vaccine, which is widely seen as the first step toward a single-payer national health care system.
A spokesman for CVS said Monday that the company would not release the numbers.
The Seattle company announced a few months ago that it would begin distributing its meningociscid vaccine to people who had been previously vaccinated with the CVR, the second-generation meningose immune system.
The company also is in talks with doctors to administer CVS’s vaccine.
The vaccine has been around for nearly 30 years, and it was first marketed to the public in 1985.
Its main benefits are reduced inflammation in the lungs, which protects against the coronavirus that has killed about 80,000 people.
The vaccine’s effectiveness is also attributed to it being safe to use.
In fact, it’s not even recommended for people with a history of CVS or a history or current medical condition that might make them more susceptible to COVID-19.
But Stadlers said that while many people would like to avoid the coronas, the vaccine is being offered as a “first-of-its-kind” option.
She said that CVS expects to see about 5,000 doses of the CVA vaccine in its stores in Seattle, Tacoma and Seattle’s Westlake neighborhood.